PCN51 HEALTH CARE COSTS ASSOCIATED WITH ANGIOGENESIS INHIBITORS (AIS) AND MTOR INHIBITORS (MTORS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED AT US COMMUNITY ONCOLOGY CLINICS
Abstract
Authors
K Chen SP Sarda L Antrs S Whittemore A Luka P Ramamurthy J Scott B Fortner MP Neary MS Duh P Jolly